Search Results for keywords:"hearing request"

The Drug Enforcement Administration (DEA) has announced that Siegfried USA, LLC, located in Pennsville, New Jersey, has applied to be registered as a bulk manufacturer of certain controlled substances. Interested parties, including registered manufacturers of these substances, can submit comments or objections electronically by March 24, 2025. They can also request a hearing on the application by the same date. This registration will allow Siegfried USA to produce these substances in bulk for sale.

Patheon API Services Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. This registration is intended to support the clinical trials of their customers. Interested parties are invited to submit comments or objections electronically through the Federal eRulemaking Portal by June 17, 2025. They may also request a hearing on the application by the same date.

Cedarburg Pharmaceuticals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The company plans to produce synthetic Tetrahydrocannabinols (THC) as an active pharmaceutical ingredient for distribution. Interested parties, including current manufacturers or applicants, can submit comments or request a hearing regarding this application by March 15, 2021. The DEA is handling correspondence related to this application.

The U.S. Nuclear Regulatory Commission (NRC) issued an order prohibiting David Huey, a former manager at Titan Inspections, Inc., from participating in NRC-licensed activities for three years. This decision was made because he instructed a radiographer to work without a second qualified person present, which violated NRC regulations. The order requires Huey to immediately cease any NRC-licensed activities and notify the NRC of any new employment in such activities after the prohibition period. Huey and anyone affected by this order have the right to request a hearing within 30 days of its publication in the Federal Register.

Stepan Company has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. This request was made on January 31, 2025, and is currently open for public comment until June 17, 2025. Individuals who are already registered manufacturers of these substances or are applicants for such a registration can submit their comments or objections electronically through the Federal eRulemaking Portal. Interested parties may also request a hearing on this application before the deadline if desired.

S&B Pharma, Inc. has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances. The company intends to import intermediate forms of Tapentadol for manufacturing purposes and ANPP to produce other controlled substances, but they will not import finished products for commercial sale. Interested parties, such as registered manufacturers, can submit comments, objections, or request a hearing regarding this application by March 18, 2021.

The U.S. Nuclear Regulatory Commission (NRC) has received a request from American Centrifuge Operating, LLC to amend a license allowing operations at the American Centrifuge Plant in Piketon, Ohio, for an additional nine years beyond June 30, 2025. This request, which involves sensitive information, includes prolonged operations producing high-assay low-enriched uranium for the Department of Energy. Interested parties can request a hearing or petition to intervene by specific deadlines and must follow procedures to access the sensitive information. The NRC will review the application before making a decision.

In a notice from the Securities and Exchange Commission (SEC), an application was submitted under the Investment Company Act of 1940. The applicants, including Privacore PCAAM Alternative Income Fund and others, are seeking exemptions to allow certain investment companies to issue multiple share classes with asset-based distribution or service fees and early withdrawal charges. A hearing on the application may occur if requested by December 23, 2024. Public comments and hearing requests can be submitted via email, and further information is available on the SEC's EDGAR system.